摘要
目的探讨莉芙敏联合帕罗西丁治疗围绝经期抑郁症的疗效和安全性。方法将围绝经期抑郁症患者120例数字随机分为治疗组和对照组，每组各60例，其中治疗组给予莉芙敏每次1片，2次／d，口服，和帕罗西丁20mg，1次／d，口服；对照组仅给予帕罗西丁20mg，1次／d，口服。连续服用2个月后，观察治疗前后各组汉密尔顿抑郁量表（HAMD）评分及考普曼（Kupperman）评分法评估疗效，并对比治疗前后血常规、尿常规、心电图、肝肾功和血压等，评定不良反应。结果通过HAMD评分比较，对于围绝经期抑郁症的改善，治疗组的总有效率为88．3％，对照组总有效率为78．3％，治疗组疗效显著高于对照组（P〈0．05）；治疗8周后，治疗组和对照组的KMI评分分别为（9．89±3．76）分和（15．75±5．84）分，两组比较，差异有统计学意义（P〈0．01）；联合用药明显优于单用帕罗西丁组。两组治疗前后血常规、尿常规、肝肾功、心电图和血压等无明显变化，差异无统计学意义（P〉0．05）。结论莉芙敏联合帕罗西丁对围绝经期的抑郁程度有缓解作用，安全性高且不良发应少，患者易接受，值得临床进一步推广研究。
Objective To explore the efficacies and safety of combined treatment of remifemin and paroxetine for perimenopausal depression. Methods A total of 120 patients with perimenopausal depression were digital randomly divided into the treatment and control groups （ n = 60 each）. The treatment group received oral remifemin one tablet twice daily and paroxetine 20 mg once daily for 2 months while the control group oral paroxetine 20 mg once daily for 2 months. The Hamilton depression scale （HAMD） and Kupperman scale were used to assess the therapeutic efficacies. Blood and urine routine, electrocardiography, liver function, kidney function and blood pressure before and after treatment were examined to assess the side effects. Results For the improvement of perimenopausal depression on HAMD, the total effective rates of the treatment and control groups were 88. 3% and 78. 3% respectively. The therapeutic efficacy of the treatment group was significantly higher than that of the control group（ P 〈 0. 05 ）. After 8-week treatment, Kupperman menopausal indices of the treatment and control groups were 9.89 ± 3.76 and 15.75± 5.84 respectively. There was also significant difference （ P 〈 0. 01 ）. No significant changes existed in blood routine, urine routine, liver function, kidney function, blood pressure, ECG or blood pressure before and after treatment （P 〉 0. 05）. Conclusion The combined treatment of remifemin and paroxetine for perimenopausal depression can improve the efficacies. It is easily accepted by patients for its higher safety and fewer side-effects. It is worthy of a wider application and further researches.
出处
《中华医学杂志》
CAS
CSCD
北大核心
2013年第8期600-602,共3页
National Medical Journal of China
关键词
抑郁症
更年期
莉芙敏
帕罗西丁
Depressive isorder, major
Remiferain
Paroxetine
作者简介
通信作者：黄彦生，450003，Email：yanshenghuangcn@yahoo．com.cn
